(Q41233891)

28 September 2017

title

Salmonella flagellin is a potent carrier-adjuvant for peptide conjugate to induce peptide-specific antibody response in mice (English)

1 reference

28 September 2017

Feng Qian

1

1 reference

28 September 2017

Aihua Guo

2

1 reference

28 September 2017

Mengmeng Li

3

1 reference

28 September 2017

Wei Liu

4

1 reference

28 September 2017

Zhiming Pan

5

1 reference

28 September 2017

Lei Jiang

6

1 reference

28 September 2017

Xin Wu

7

1 reference

28 September 2017

Huji Xu

8

1 reference

28 September 2017

language of work or name

English

0 references

publication date

10 March 2015

1 reference

28 September 2017

1 reference

28 September 2017

volume

33

1 reference

28 September 2017

issue

17

1 reference

28 September 2017

page(s)

2038-2044

1 reference

Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Innate and adaptive immune responses to viral infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

'Toll' gates for future immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Toll or toll-free adjuvant path toward the optimal vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Salmonella flagellin fused with a linear epitope of colonization factor antigen I (CFA/I) can prime antibody responses against homologous and heterologous fimbriae of enterotoxigenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Production and characterization of peptide antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Plasmodium falciparum: exported protein-1, a blood stage antigen, is expressed in liver stage parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

A malaria protein exported into a new compartment within the host erythrocyte.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Organization of ETRAMPs and EXP-1 at the parasite-host cell interface of malaria parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Recognition of synthetic polypeptides corresponding to the N- and C-terminal fragments of Plasmodium falciparum Exp-1 by T-cells and plasma from human donors from African endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

The use of maleimidocaproyloxysuccinimide to prepare malarial peptide carrier immunogens. Immunogenicity of the linking region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Plasmodium falciparum enolase: stage-specific expression and sub-cellular localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Flagellin as an adjuvant: cellular mechanisms and potential.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

A mouse model of Salmonella typhi infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Transcriptional regulation of Tlr11 gene expression in epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

Inhibitory monoclonal antibody against a (myristylated) small-molecular-weight antigen from Plasmodium falciparum associated with the parasitophorous vacuole membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.03.006

1 reference

28 September 2017

1 reference